ArticleJournal of assisted reproduction and genetics2025
A signature serum biomarker for non-invasive diagnosis of preeclampsia patients.
Article in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study seeks to identify a non-invasive biomarker for preeclampsia (PE), given its considerable influence on both maternal and fetal health.
methodsThe identification of differentially expressed genes (DEGs) in PE serum was conducted utilizing GSE192902. Weighted gene co-expression network analysis (WGCNA) was employed to identify functional modules, which were subsequently evaluated for their biological functions. Binary logistic regression was employed to evaluate genes derived from the intersection of DEGs and the most correlated module, with the aim of developing a biomarker model. The analysis of placental gene expression profiles was conducted utilizing GSE234729, and the model underwent validation in GSE149437.
resultsOver 1500 DEGs were identified in the serum of PE patients, with 63% exhibiting downregulation. Co-expression analysis revealed that the expression patterns of PE are structured into 13 distinct modules, with the dark-red module, comprising 55 genes, demonstrating the most significant correlation to the onset of PE. Following this, eight genes from the 26 differentially expressed genes (ADRB1, ARX, C2orf72, FOXB2, HIC1, IRX4, MEX3D, and MIR6724-4) were employed to construct a biomarker model, which attained an area under the curve of 76% (95% CI: 69-83%) in the training cohort and 74% (95% CI: 61-87%) in the validation cohort. Six DEGs were identified from the intersection of results pertaining to serum, placenta, and the dark-red module. However, only two, C2orf72 and RASGEF1C, exhibited consistent downregulation in both placenta and blood.
conclusionThis comprehensive analysis reveals a promising biomarker model that may facilitate early detection of PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.